GlassScriptPhysician profile
Peter L Bergsagel
NPI 1316920150
$15,315.13
in general payments reported to CMS, 2019-2025
12 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $5,000 · 2021: $4,578 · 2022: $167 · 2023: $3,450 · 2024: $102 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,085 · Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,085.00 |
| Food and Beverage | $484.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,000.00 | 2020 | |
| Pfizer INC. | $4,538.37 | 2023-2025 | |
| Janssen Research & Development, LLC | $4,290.00 | 2021 | |
| Abbvie INC. | $675.00 | 2023 | |
| Janssen Biotech, INC. | $397.37 | 2021-2023 | Darzalex, Tecvayli, Carvykti |
| Tempus Ai, INC | $127.26 | 2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $119.78 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $119.32 | 2022 | |
| Karyopharm Therapeutics INC. | $48.03 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bergsagel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.